FDA has approved updated label changes for the smoking cessation drug, varenicline (Chantix, Pfizer).
FDA has approved updated label changes for the smoking cessation drug, varenicline (Chantix, Pfizer).
The updated label will include data from a meta-analysis of 5 clinical trials that showed no increased risk in the incidence of suicidal ideation and/or behavior in patients taking Chantix versus a placebo.
The warnings and precautions section also includes updates on alcohol use and seizures.
READ: Varenicline and cardiovascular risk
Patients are now instructed to reduce the amount of alcohol they consume until they know how Chantix affects their alcohol tolerance, according to drug maker Pfizer.
The label also advised that Chantix should be used with caution by patients with a history of seizures “or other factors that can lower the seizure threshold.”
Pfizer will be discussing the changes with an FDA advisory committee on October 16, according to the company. They also plan to ask the agency to remove the “black box” warning on the Chantix label.
A black box warning is FDA’s strongest medication-related safety warning and highlights major risks. According to the FDA, “drugs that have special problems, particularly ones that may lead to death or serious injury, may have this warning information displayed within a box in the prescribing information... Drugs that have such boxed warnings are not permitted to have reminder ads."
FDA announced July 1, 2009 that it would require Chantix to carry a black-box warning.
More than 10 million smokers in the United States have been prescribed Chantix. It was approved for use by FDA in May 2006.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More